Yamamoto-Furusho J K, Bosques-Padilla F
Clínica de Enfermedad inflamatoria Intestinal, Departamento de Gastroenterología Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, México D.F.
Rev Gastroenterol Mex. 2009;74(3):263-78.
Inflammatory bowel disease is a chronic and relapsing disorder without any curative medical treatment. Different drugs have been focused to get clinical remission during the flare, maintenance of remission and improving the quality of life of inflammatory bowel disease patients. Recently, new therapeutic agents blocking the tumoral necrosis factor alpha, a pro-inflammatory cytokine have been approved for the use in these kind of patients.
To establish the first Mexican Consensus for the use of anti tumoral necrosis factor alpha agents in the treatment of patients with inflammatory bowel disease.
A group of gastroenterologist and colorectal surgeons from different regions of the country were invited to attend to this meeting. The consensus was divided in 7 sections and a total of 53 items were evaluated for all participants. The Delphi system was used in this consensus and several clinical trials were considered in order to provide recommendations according to evidence based medicine. Finally, conclusions were obtained after discussing all items.
This is the first mexican Consensus that provides the recommendations about the use of anti tumoral necrosis factor alpha agents in inflammatory bowel disease patients
It is important to have a deep knowledge about the anti tumoral necrosis factor alpha in the following conditions: indications and contraindications; parameters of clinical efficacy; predicting factors of medical treatment response; strategies for preventing and treating immunogenicity; efficacy and safety as well as the clinical factors for using these agents as first line of therapy (top-down).
炎症性肠病是一种慢性复发性疾病，尚无根治性药物治疗。不同药物一直致力于在发作期实现临床缓解、维持缓解以及改善炎症性肠病患者的生活质量。最近，阻断肿瘤坏死因子α（一种促炎细胞因子）的新型治疗药物已获批用于此类患者。
建立墨西哥首个关于使用抗肿瘤坏死因子α药物治疗炎症性肠病患者的共识。
邀请了来自该国不同地区的一组胃肠病学家和结直肠外科医生参加此次会议。共识分为7个部分，共53项内容供所有参与者评估。本共识采用德尔菲系统，并参考了多项临床试验，以便根据循证医学提供建议。最后，在讨论所有项目后得出结论。
这是首个关于在炎症性肠病患者中使用抗肿瘤坏死因子α药物的墨西哥共识。
在以下情况中深入了解抗肿瘤坏死因子α很重要：适应证和禁忌证；临床疗效参数；药物治疗反应的预测因素；预防和治疗免疫原性的策略；疗效和安全性以及将这些药物作为一线治疗（自上而下）的临床因素。
